Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Shee, Kevin; Calle, Claire M. de la; Chang, Albert; Wong, Anthony; Feng, Felix Y.; Gottschalk, Alexander; Carroll, Peter R.; Nguyen, Hao G.

doi:10.1016/j.adro.2022.100941

Advances in Radiation Oncology

2022

DOI: 10.1016/j.adro.2022.100941

|View full text |Cite

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Kevin Shee

Claire M. de la Calle

Albert Chang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on Enzalutamide having a higher affinity to the androgen receptor than bicalutamide, there are a lot of ongoing studies that combine enzalutamide to treat patients who are undergoing radiation therapy (RT) for prostate cancer. We were intrigued by the article by Shee et al, 1 which demonstrated the safety and efficacy of Enzalutamide in combination with standard androgen deprivation therapy and RT. However, some questions were raised after reading the manuscript.…”

mentioning

confidence: 99%

In Regard to Shee et al

Senyurek

Sezen²,

Bölükbaşı³

2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

mentioning

confidence: 99%

In Regard to Shee et al

Senyurek

Sezen²,

Bölükbaşı³

2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer

Wang

Lee²,

Armstrong³

2022

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials

Shelan,

Achard,

Appiagyei

et al. 2024

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Introduction Enzalutamide, a second-generation androgen receptor inhibitor, is indicated for the treatment of metastatic disease, as well as in the treatment of non-metastatic castration resistant prostate cancer (PCa). This systematic review aims to determine outcomes and toxicity in patients with non-metastatic castration sensitive prostate cancer (nmCSPC) treated with enzalutamide in the primary or salvage settings. Method We performed a systematic review focusing on the role of Enzalutamide in the treatment of nmCSPC, using the PubMed/Medline database. Articles focusing on androgen receptor inhibitors in nmCSPC were included, while articles discussing exclusively metastatic or castration-resistant PCa were excluded. Results The initial search retrieved 401 articles, of which 15 underwent a thorough assessment for relevance. Ultimately, 12 studies with pertinent outcomes were meticulously examined. Among these, seven studies were dedicated to the investigation of enzalutamide in the primary setting, while the remaining five publications specifically addressed its use in salvage settings. Regardless of the treatment setting, our data revealed two distinct therapeutic strategies. The first advocates for the substitution of enzalutamide for androgen deprivation therapy (ADT), based on the premise of achieving equivalent, if not superior, oncological outcomes while minimizing treatment-related toxicity. The second, adopting a more conventional approach, entails augmenting the effectiveness of ADT by incorporating enzalutamide. Conclusion Enzalutamide has considerable potential as a therapeutic strategy for nmCSPC, either used alone or in combination with ADT in the primary or in the salvage settings. The use of enzalutamide instead of ADT is an appealing strategy. However, more trials will be required to further understand the efficacy and side-effect profile of enzalutamide monotherapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Cited by 4 publications

References 44 publications

In Regard to Shee et al

In Regard to Shee et al

Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer

Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials

Contact Info

Product

Resources

About